BDBM165347 US9062043, Table 13, Compound 13::US9062043, Table 20b, Compound 9

SMILES OC(=O)c1ccc2c(c1)nc(Nc1ccc(F)c(Cl)c1)c1ncncc21

InChI Key InChIKey=WSXPHOLBCMJTBO-UHFFFAOYSA-N

Data  4 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 165347   

TargetCasein kinase II subunit alpha(Human)
Senhwa Biosciences

US Patent
LigandPNGBDBM165347(US9062043, Table 20b, Compound 9 | US9062043, Tabl...)
Affinity DataIC50: 10nMpH: 7.2Assay Description:Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2016
Entry Details
US Patent

TargetCasein kinase II subunit alpha'(Human)
University of North Carolina at Chapel Hill

Curated by ChEMBL
LigandPNGBDBM165347(US9062043, Table 20b, Compound 9 | US9062043, Tabl...)
Affinity DataIC50: 19nMAssay Description:Inhibition of C-terminal Nano-Luc fused human CK2alpha' expressed in HEK293 cells using NanoBRET NanoGlo substrate in presence of tracer K5 by NanoBR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/22/2024
Entry Details
PubMed
TargetCasein kinase II subunit alpha(Human)
Senhwa Biosciences

US Patent
LigandPNGBDBM165347(US9062043, Table 20b, Compound 9 | US9062043, Tabl...)
Affinity DataIC50: 110nMAssay Description:Inhibition of C-terminal Nano-Luc fused human CK2alpha expressed in HEK293 cells using NanoBRET NanoGlo substrate in presence of tracer K10 by NanoBR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/22/2024
Entry Details
PubMed
TargetCasein kinase II subunit alpha(Human)
Senhwa Biosciences

US Patent
LigandPNGBDBM165347(US9062043, Table 20b, Compound 9 | US9062043, Tabl...)
Affinity DataIC50: 1.06E+3nMpH: 7.4Assay Description:The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2016
Entry Details
US Patent